|
Open Orphan PLC - London-based pharmaceutical services - For 2021, expects to report earnings before interest, tax, depreciation and amortisation, on revenue which is set to be £40 million, up from £20.6 million in 2020. For 2022, the company is targeting £50 million in non-Covid work revenue.
Will also be expanding its facilities through the opening of the Whitechapel quarantine clinic in London and the Queen Mary's Bioenterprises Centre clinic in Manchester.
‘Despite difficult market conditions during the year, which have continued into 2022, I am pleased with the performance of the Open Orphan team and during 2021 we signed an impressive number of human challenge study contracts with Big Pharma and biotechnology clients,’ says Executive Chair Cathal Friel.
‘We have continued our strong work at the start of this year, and our new facilities in both London and Manchester will not only enable the company to screen a greater number of potential volunteers, it will also increase our total bed count to 62,’ Friel adds.
Current stock price: 11.50 pence
12-month change: down 55%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
